Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04)-Reference-Cited by-同舟云学术

Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04)

Published:2016-03-21 Issue:6 Volume:103 Page:676-685
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Murayama Tohru,Fukuda Takahiro,Okumura Hirokazu,Sunami Kazutaka,Sawazaki Aiko,Maeda Yoshinobu,Tsurumi Hisashi,Uike Naokuni,Hidaka Tomonori,Takatsuka Yoshifusa,Eto Tetsuya,Tsuda Hiroyuki,Fujisaki Tomoaki,Miyamoto Toshihiro,Tsuneyoshi Naoko,Iyama Satoshi,Nagafuji Koji,Harada Mine

Funder

Regional Medicine Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-016-1976-4.pdf

Reference36 articles.

1. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–18.

2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

3. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de L’Adulte. J Clin Oncol. 2005;23:4117–26.